1 to 9 of 13 results

Infinity amends PI3K-delta, gamma accord with Millennium


US drug discovery firm Infinity Pharmaceuticals (Nasdaq: INFI) says it has amended its development and…

BiotechnologyFinancialInfinity PharmaceuticalsIPI-145LicensingMillennium PharmaceuticalsPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

Novel therapeutic agents presented at ASH provide hope for patients with hard-to-treat blood disorders


Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting…

Ambit BiosciencesBiotechnologyIncyteMillennium PharmaceuticalsMLN9708NovartisOncologyPharmaceuticalquizartinibResearchruxolitinibTakeda Pharmaceuticals

European Commission grants conditional approval for Adcetris


Millennium, a wholly owned subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502)…

AdcetrisBiotechnologyEuropeMillennium PharmaceuticalsOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

More highlights from ESMO Congress


In further news coming out at the European Society of Medical Oncology (ESMO) Congress taking place in…

AdcetrisAstellas PharmaBiotechnologydabrafenibGlaxoSmithKlineImmunoGenMedivationMillennium PharmaceuticalsOncologyPharmaceuticalResearchRocheSeattle GeneticsT-DM1Takeda Pharmaceuticalstrastuzumab emtansineXtandi

Takeda unit posts updated survival data with HL drug candidate Adcetris


USA based Millennium, a wholly owned oncology subsidiary of Takeda Pharmaceutical (TYO: 4502), yesterday…

AdcetrisMillennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda Pharmaceuticals

Millennium is first industry partner in collaboration to advance personalized medicine for multiple myeloma


The Multiple Myeloma Research Foundation (MMRF) t that it has entered into a multi-year collaboration…

Millennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda Pharmaceuticals

US FDA approves Seattle Genetics’ Adcetris to treat two types of lymphoma


Shares of US biotech firm Seattle Genetics Nasdaq: SGEN) gained 8% to $15.09 late Friday, after the US…

AdcetrisBiotechnologybrentuximabMillennium PharmaceuticalsNorth AmericaOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Takeda’s Millennium files two sNDAs for Velcade with US FDA


Japan’s largest drugmaker, Takeda Pharmaceutical (TSE: 4502), together with its US oncology subsidiary…

BiotechnologyMillennium PharmaceuticalsNorth AmericaOncologyPharmaceuticalRegulationTakeda PharmaceuticalsVelcade

1 to 9 of 13 results



Back to top